1626 related articles for article (PubMed ID: 28238195)
1. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
2. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
Bahrami B; Hong T; Schlub TE; Chang AA
Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
[TBL] [Abstract][Full Text] [Related]
3. Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.
Laiginhas R; Silva MI; Rosas V; Penas S; Fernandes VA; Rocha-Sousa A; Carneiro Â; Falcão-Reis F; Falcão MS
Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):83-89. PubMed ID: 29082448
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
5. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
[TBL] [Abstract][Full Text] [Related]
6. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
Shah CP; Heier JS
Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab.
Ebrahimiadib N; Lashay A; Riazi-Esfahani H; Jamali S; Khodabandeh A; Zarei M; Roohipoor R; Khojasteh H; Bazvand F; Ojani M; Shahabinejad M; Yaseri M; Modjtahedi BS; Davoudi S; Riazi-Esfahani M
Ophthalmic Surg Lasers Imaging Retina; 2020 Mar; 51(3):145-151. PubMed ID: 32211904
[TBL] [Abstract][Full Text] [Related]
8. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
Chen YY; Chang PY; Wang JK
Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
[TBL] [Abstract][Full Text] [Related]
10. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.
Ashraf M; Souka AA; ElKayal H
Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):230-236. PubMed ID: 28297035
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial.
Ahmadieh H; Nourinia R; Hafezi-Moghadam A; Sabbaghi H; Nakao S; Zandi S; Yaseri M; Tofighi Z; Akbarian S
Br J Ophthalmol; 2019 Jul; 103(7):922-927. PubMed ID: 30150280
[TBL] [Abstract][Full Text] [Related]
13. Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema.
Campos A; Campos EJ; do Carmo A; Patrício M; Castro de Sousa JP; Ambrósio AF; Silva R
Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1857-1865. PubMed ID: 30039271
[TBL] [Abstract][Full Text] [Related]
14. Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs.
Ibrahim WS; Eldaly ZH; Saleh MG; Rateb MF; Aldoghaimy AH
Korean J Ophthalmol; 2019 Apr; 33(2):122-130. PubMed ID: 30977321
[TBL] [Abstract][Full Text] [Related]
15. Correlation of Macular Thickness and Visual Acuity in DME Treated by Two Doses of Intravitreal Ziv-Aflibercept Versus Bevacizumab: Analysis of a Randomized, Three-Armed Clinical Trial.
Jabbarpoor Bonyadi MH; Baghi A; Ramezani A; Yaseri M; Soheilian M
Ophthalmic Surg Lasers Imaging Retina; 2019 Nov; 50(11):684-690. PubMed ID: 31755967
[TBL] [Abstract][Full Text] [Related]
16. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
[TBL] [Abstract][Full Text] [Related]
17. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
[TBL] [Abstract][Full Text] [Related]
18. One-Year Results of Treatment of Diabetic Macular Edema with Aflibercept Using the Treat-and-Extend Dosing Regimen: the VIBIM Study.
Pak KY; Shin JP; Kim HW; Sagong M; Kim YC; Lee SJ; Chung IY; Park SW; Lee JE
Ophthalmologica; 2020; 243(4):255-262. PubMed ID: 31914437
[TBL] [Abstract][Full Text] [Related]
19. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study.
Barakat MR; Wykoff CC; Gonzalez V; Hu A; Marcus D; Zavaleta E; Ciulla TA
Ophthalmol Retina; 2021 Jan; 5(1):60-70. PubMed ID: 32829027
[TBL] [Abstract][Full Text] [Related]
20. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.
Jampol LM; Glassman AR; Bressler NM; Wells JA; Ayala AR;
JAMA Ophthalmol; 2016 Dec; 134(12):. PubMed ID: 27711918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]